Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Introduction Several prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum‐based therapy can be used to predict the efficacy of poly(adenosine diphosphate‐ribose) polymerase inhibitors such as olaparib. Case pres...

Full description

Bibliographic Details
Main Authors: Yoshiyuki Miyazawa, Takanori Shimizu, Yoshitaka Sekine, Seiji Arai, Akira Ohtsu, Yuji Fujizuka, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:IJU Case Reports
Subjects:
prostate cancer
castration‐resistant prostate cancer
neuroendocrine prostate cancer
poly(adenosine diphosphate‐ribose) polymerase
BRCA
Online Access:https://doi.org/10.1002/iju5.12543

Internet

https://doi.org/10.1002/iju5.12543

Similar Items